Cost-effectiveness of using sodium-glucose cotransporter type 2 inhibitors as a part of therapy for cardiovascular death prevention and achieving the Reduction of Cardiovascular Mortality indicator of the Healthcare Development state program in patients with chronic kidney disease and resistant hypertension
https://doi.org/10.15829/15604071-2025-6330
EDN: YCVRNM
Abstract
Aim. To assess cost-effectiveness of using sodium-glucose cotransporter type 2 (SGLT2) inhibitors as a part of therapy for cardiovascular death prevention and achieving the Reduction of Cardiovascular Mortality indicator of the Healthcare Development state program in patients with chronic kidney disease (CKD) and resistant hypertension (RH).
Material and methods. The target population is Russian comorbid patients with CKD and RH. The population size of 263303 people was determined based on Russian statistical data, literary sources and assumptions adopted in the study. To predict cardiovascular death, parametric modeling was used based on published clinical trial data. We calculated the drug costs required to prevent one cardiovascular death, as well as to achieve a target indicator for reducing cardiovascular mortality by one percent when using SGLT2 inhibitors in Russia as a whole and separately in each region.
Results. The costs of CKD therapy in working-age patients with RH, who are indicated for therapy with SGLT2 inhibitors (n=263303) in 2025 were RUB 7,6 billion. The use of standard therapy with SGLT2 inhibitors in the target group of patients will prevent 2273 cardiovascular death cases in the first year, which will ensure the achievement of the Reduction of Cardiovascular Mortality indicator of the Healthcare Development state program by 9,9%.
Conclusion. The ratio of additional costs to life years gained was RUB 2,49 million, which does not exceed 3 times the gross domestic product per capita (RUB 3,51 million) and indicates the economic feasibility of SGLT2 inhibitor therapy for CKD in patients with RH.
About the Authors
M. V. ZhuravlevaRussian Federation
Moscow
Yu. V. Gagarina
Russian Federation
Moscow
T. V. Marin
Russian Federation
Moscow
References
1. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) doi:10.15829/1560-4071-2024-6117. EDN GUEWLU.
2. Yan AT, Yan RT, Tan M, et al. Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes. Can J Cardiol. 2006; 22(2):115-20. doi:10.1016/s0828-282x(06)70249-5.
3. Yagudina RI, Serpik VG, Abdrashitova GT, Kotenko ON. The economic burden of chronic kidney disease in the Russian Federation. Pharmacoeconomics: theory and practice. 2014;2(4):40-5. (In Russ.) doi:10.30809/phe.4.2014.5.
4. McCullough PA, Li S, Jurkovitz CT, et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008;51(4 Suppl 2):S38-45. doi:10.1053/j.ajkd.2007.12.017.
5. Balanova YuA, Kontsevaya AV, Myrzamatova AO, et al. The economic damage caused by arterial hypertension due to its contribution to morbidity and mortality from major chronic noncommunicable diseases in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2020;16(3):415-23. (In Russ.) doi:10.20996/1819-6446-2020-05-03.
6. Heerspink HJL, Stefánsson BV, Correa-Rotter R. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436-46.
7. Patel SM, Kang YM, Im K, et al. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis. Circulation. 2024;149(23):1789-801. doi:10.1161/CIRCULATIONAHA.124.069568.
8. Chen X, Wang J, Lin Y, et al. Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients. Front Endocrinol (Lausanne). 2023;14:1236404. doi:10.3389/fendo.2023.1236404.
9. Borg R, Kriegbaum M, Grand MK, et al. Chronic kidney disease in primary care: risk of cardiovascular events, end stage kidney disease and death. BMC Prim Care. 2023;24(1):128. doi:10.1186/s12875-023-02077-7.
10. Wheeler DC, Stefansson BV, Batiushin M, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020;35(10):1700-11. doi:10.1093/ndt/gfaa234.
11. Reyes-Farias CI, Reategui-Diaz M, Romani-Romani F, et al. The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: A systematic review and metaanalysis. PLoS ONE. 2023;18(11):e0295059. doi:10.1371/journal.pone.0295059.
12. Kofod DH, Carlson N, Ballegaard EF, et al. Cardiovascular mortality in patients with advanced chronic kidney disease with and without diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2023;22(1):140. doi:10.1186/s12933-023-01867-8.
13. The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2022;388:117-27. doi:10.1056/NEJMoa2204233.
14. Perkovic V, Jardine MJ, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-306. doi:10.1056/NEJMoa1811744.
15. Kotenko ON, Omelyanovsky VV, Ignatieva VI, et al. The cost of chronic kidney disease in the Russian Federation. Clinical nephrology. 2021;4:30-8. (In Russ.)
16. Thomas G, Xie D, Chen HY, et al. Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study. Hypertension. 2016;67(2):387-96.
17. Zhuravleva MV, Nedogoda SV, Gagarina YuV, Marin TV. Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction. Russian Journal of Cardiology. 2024;29(7):6027. (In Russ.) doi:10.15829/1560-4071-2024-6027. EDN ZIARUH.
18. Mukhortova PA, Bessonova TO, Teryan RA, et al. A clinical and economic assessment of the feasibility of including PCSK9 inhibitors in the list of medicines for preferential outpatient drug provision (list "23 INN") for secondary prevention of cardiovascular events. Medical technologies. Assessment and selection. 2022;(4):51-62. (In Russ.)
Supplementary files
Review
For citations:
Zhuravleva M.V., Gagarina Yu.V., Marin T.V. Cost-effectiveness of using sodium-glucose cotransporter type 2 inhibitors as a part of therapy for cardiovascular death prevention and achieving the Reduction of Cardiovascular Mortality indicator of the Healthcare Development state program in patients with chronic kidney disease and resistant hypertension. Russian Journal of Cardiology. 2025;30(4):6330. (In Russ.) https://doi.org/10.15829/15604071-2025-6330. EDN: YCVRNM